Trulieve Cannabis Corp (TCNNF)

Trulieve Cannabis and Green Thumb Industries are already two of the top cannabis retailers in the U.S. The Department of Justice reclassification makes them even stronger.

New cannabis rules boost medical-only profits while challenging multi-state operators.

These companies are major players in the U.S. marijuana market, and they all generated more than $1 billion in revenue last year.

The Trump administration recently rescheduled medical marijuana from a Schedule I to Schedule III substance.

In a paradoxical display of market confidence, shares of Tilray Brands (NASDAQ:TLRY) surged over 8% on Wednesday following the release of its fiscal third-quarter 2026 financial results. While the company delivered a "record" revenue performance of $206.7 million, outstripping analyst estimates of $201.3 million, it fell significantly

As of January 9, 2026, the cannabis sector finds itself at a historic crossroads, caught between the euphoria of federal progress and the harsh reality of market mechanics. Following a landmark Executive Order in late 2025 aimed at accelerating the rescheduling of marijuana, the industry has entered the new year

Not all of these predictions may come true. But at least a few of them will likely do so.

President Donald Trump just signed an executive order that reclassified marijuana from a Schedule I narcotic to Schedule III.

These cannabis companies could soon see more green thanks to the president's milestone decision.

Trump's historic executive order to reclassify cannabis isn't the victory it appears to be.

The cannabis sector is experiencing a historic "Santa Claus rally" this December, with stock prices surging across the board following a transformative shift in federal policy. Today, December 19, 2025, markets are still reeling from yesterday’s decisive executive action aimed at ending the federal gridlock that has plagued the

In a move that has sent shockwaves through the global financial markets, the cannabis sector is currently navigating a period of unprecedented volatility following a landmark regulatory shift. On December 18, 2025, President Donald Trump signed a historic Executive Order directing the Attorney General to expedite the reclassification of marijuana

A shift in federal marijuana policy could be coming.

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare.

The weed purveyor's latest quarter featured a net loss, but it's been worse in the past.

Congress is being lobbied to tighten regulations on hemp products throughout the U.S.

This top pot stock feels like a solid contrarian play while the weed industry is generally down.

Cannabis stocks and ETFs skyrocketed after Trump hinted at reclassifying marijuana. Tilray surged 35% in 2 days. Other top performers included Trulieve, Tilray, Curaleaf, and Canopy Growth. This shift could ease federal regulations and improve the industry's growth potential.